Manufacturers: Nurix Therapeutics
Bexobrutideg (NX-5948), a next-generation BTK degrader from Nurix (NURIX), is listed among the emerging agents intended to address relapsed/refractory Waldenström macroglobulinemia and to overcome resistance to covalent BTK inhibitors. DelveInsight's market analysis notes it may establish a differentiated position through its BTK degradation mechanism, which could help overcome resistance-associated mutations and support adoption in heavily pretreated patients.
Bexobrutideg (NX-5948), a next-generation BTK degrader from Nurix (NURIX), is listed among the emerging agents intended to address relapsed/refractory Waldenström macroglobulinemia and to overcome resistance to covalent BTK inhibitors. DelveInsight's market analysis notes it may establish a differentiated position through its BTK degradation mechanism, which could help overcome resistance-associated mutations and support adoption in heavily pretreated patients.
3 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
